Of particular interest were drugs predicted to modulate the NFE2L2 gene, including Lagascatriol, Andalusol, Irofulven, NK-252, RTA-408, and Sulforaphane, which are commonly employed to alleviate inflammation associated with RA in clinical practice. The gene discussed is NFE2L2; the disease is rheumatoid arthritis.